Abstract
MicroRNAs are post-transcriptional regulators of gene expression with tissue-specific expression profiles. Dysregulation of microRNAs has been shown to play a role in carcinogenesis. Although progress has been made in the diagnosis and treatment of many cancers, pancreatic cancer remains an intractable public health problem, causing 6.58% of cancer deaths despite making up less than 3% of cancer diagnoses in the United States. No screening, diagnostic or imaging techniques exist with the sensitivity to detect pancreatic cancer in its early, operable stages. Risk factors include numerous inherited syndromes, diabetes mellitus, and hepatitis C virus infection. Here we review the literature regarding dysregulation of microRNA expression in native pancreas, pancreatic ductal adenocarcinoma (the dominant form of pancreatic cancer), and its risk factors to illuminate the biology and progression of this disease. We explore promising evidence for the use of microRNAs as prognostic and diagnostic tools, and discuss emerging reports on microRNA therapeutics.
Keywords: Biomarker, microRNA, pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia, carcinogenesis, malignancy, asymptomatic, papillary, serum, Endocrine.
MicroRNA
Title:No miR Quirk: Dysregulation of microRNAs in Pancreatic Ductal Adenocarcinoma
Volume: 1 Issue: 1
Author(s): Philip Y. Cheung, Anna E. Szafranska-Schwarzbach, Annette M. Schlageter, Bernard F. Andruss and Glen J. Weiss
Affiliation:
Keywords: Biomarker, microRNA, pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia, carcinogenesis, malignancy, asymptomatic, papillary, serum, Endocrine.
Abstract: MicroRNAs are post-transcriptional regulators of gene expression with tissue-specific expression profiles. Dysregulation of microRNAs has been shown to play a role in carcinogenesis. Although progress has been made in the diagnosis and treatment of many cancers, pancreatic cancer remains an intractable public health problem, causing 6.58% of cancer deaths despite making up less than 3% of cancer diagnoses in the United States. No screening, diagnostic or imaging techniques exist with the sensitivity to detect pancreatic cancer in its early, operable stages. Risk factors include numerous inherited syndromes, diabetes mellitus, and hepatitis C virus infection. Here we review the literature regarding dysregulation of microRNA expression in native pancreas, pancreatic ductal adenocarcinoma (the dominant form of pancreatic cancer), and its risk factors to illuminate the biology and progression of this disease. We explore promising evidence for the use of microRNAs as prognostic and diagnostic tools, and discuss emerging reports on microRNA therapeutics.
Export Options
About this article
Cite this article as:
Y. Cheung Philip, E. Szafranska-Schwarzbach Anna, M. Schlageter Annette, F. Andruss Bernard and J. Weiss Glen, No miR Quirk: Dysregulation of microRNAs in Pancreatic Ductal Adenocarcinoma, MicroRNA 2012; 1 (1) . https://dx.doi.org/10.2174/2211536611201010049
DOI https://dx.doi.org/10.2174/2211536611201010049 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Elevated Norepinephrine an Etiological Factor in Some Cases of Alzheimers Disease?
Current Alzheimer Research Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life
Current Diabetes Reviews Transcription Factors in Autoimmune Diseases
Current Pharmaceutical Design Pharmacology and Perioperative Considerations for Diabetes Mellitus Medications
Current Clinical Pharmacology Increasing High-Density Lipoprotein Cholesterol Through Cholesteryl Ester Transfer Protein Inhibition: A Next Step in the Fight Against Cardiovascular Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial [Hot Topic: Adrenergic Receptors as Novel Targets for Cancer Therapy (Guest Editors: D.G. Powe and F. Entschladen)]
Current Cancer Therapy Reviews Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology BeMORE: A Novel Method for Detection of Adverse Fetal Effects Induced by Drugs
Current Drug Safety Review of Evidence and Perspectives of Flavonoids on Metabolic Syndrome and Neurodegenerative Disease
Protein & Peptide Letters Leptin: From Animals to Humans
Current Pharmaceutical Design An Integrated and Disease-Oriented Growth Factor-Regulated Signal Transduction Network
Current Molecular Medicine The Role of CTLA-4 Gene Polymorphisms in Autoimmune Disease Pathogenesis: A 2012 Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) An Overview of Debenzylation Methods to Obtain 1-Deoxynojirimycin (DNJ)
Mini-Reviews in Organic Chemistry The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling
Current Pharmaceutical Design Cardiovascular Toxicity from the Perspective of Oxidative Stress, Electron Transfer, and Prevention by Antioxidants
Current Vascular Pharmacology Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design Drug-Induced Pulmonary Hypertension in Newborns: A Review.
Current Vascular Pharmacology A Facile and Economical Method to Synthesize Vildagliptin
Letters in Organic Chemistry